Korean J Hematol 2003; 38(4):
Published online December 31, 2003
© The Korean Society of Hematology
김희제, 민우성, 박윤희, 박수정, 이종욱, 진종률, 한치화, 박종원, 김춘추
가톨릭대학교 의과대학 성모병원 혈액내과,
가톨릭조혈모세포이식센터
BACKGROUND : Clinical and biologic characteristics of elderly patients with acute myeloid leukemia (AML) have not been well defined yet and there is no consensus on the appropriate treatment approach. We analyzed the outcome of these patients in terms of complete remission (CR) and the long-term life expectancy.
METHODS :
Twenty patients received mitoxantrone at the dose range of 4~8 mg/m2/ day for 3 days according to the patients´ condition based on age and performance status, low-dose cytosine arabinoside 10mg/m2 subcutaneously at every 12 hours for 10~14 days, and etoposide 100mg/day per os for 10~14 days. Most of patients achieving CR received at least 1~3 more courses of post-remission therapy with same initial regimen. Nine out of 17 patients receiving more than two courses of post-remission chemotherapy received their cryopreserved peripheral bloods stem cells after the second or third consolidation chemotherapy.
RESULTS : Overall, CR was achieved in 16 (80%) out of 20 patients and the median CR duration was 6 months (range 2~17 months). The most frequent complication during the induction chemotherapy was pneumonia (55%).
CONCLUSION :
The induction chemotherapy regimen including mitoxantrone, cytosine arabinoside, and etoposide seems to be promising in elderly AML patients in terms of CR rate, while its duration was short. Hopefully, it is necessary to develop a new post-remission therapy to maintain long-term disease-free survival in elderly AML patients.
Keywords Elderly acute myeloid leukemia, Induction chemotherapy, Complete remission
Korean J Hematol 2003; 38(4): 228-233
Published online December 31, 2003
Copyright © The Korean Society of Hematology.
김희제, 민우성, 박윤희, 박수정, 이종욱, 진종률, 한치화, 박종원, 김춘추
가톨릭대학교 의과대학 성모병원 혈액내과,
가톨릭조혈모세포이식센터
Hee Je Kim, Woo Sung Min, Yoon Hee Park, Soo Jeong Park, Jong Wook Lee, jong Youl Jin, Chi Hwa Han, Chong Won Park, Chun Choo Kim
Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, Korea.
BACKGROUND : Clinical and biologic characteristics of elderly patients with acute myeloid leukemia (AML) have not been well defined yet and there is no consensus on the appropriate treatment approach. We analyzed the outcome of these patients in terms of complete remission (CR) and the long-term life expectancy.
METHODS :
Twenty patients received mitoxantrone at the dose range of 4~8 mg/m2/ day for 3 days according to the patients´ condition based on age and performance status, low-dose cytosine arabinoside 10mg/m2 subcutaneously at every 12 hours for 10~14 days, and etoposide 100mg/day per os for 10~14 days. Most of patients achieving CR received at least 1~3 more courses of post-remission therapy with same initial regimen. Nine out of 17 patients receiving more than two courses of post-remission chemotherapy received their cryopreserved peripheral bloods stem cells after the second or third consolidation chemotherapy.
RESULTS : Overall, CR was achieved in 16 (80%) out of 20 patients and the median CR duration was 6 months (range 2~17 months). The most frequent complication during the induction chemotherapy was pneumonia (55%).
CONCLUSION :
The induction chemotherapy regimen including mitoxantrone, cytosine arabinoside, and etoposide seems to be promising in elderly AML patients in terms of CR rate, while its duration was short. Hopefully, it is necessary to develop a new post-remission therapy to maintain long-term disease-free survival in elderly AML patients.
Keywords: Elderly acute myeloid leukemia, Induction chemotherapy, Complete remission
Jung-Yeon Choi, Kwang-il Kim
Blood Res 2022; 57(S1): S1-S5Jae-Ho Yoon, Hee-Je Kim, Dae-Hun Kwak, Gi June Min, Sung-Soo Park, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, and Woo-Sung Min
Blood Res 2017; 52(3): 174-183Suk-young Lee, Se Ryeon Lee, Won Jin Chang, Hye Sook Kim, Byung Soo Kim, and In Sun Kim
Korean J Hematol 2012; 47(2): 150-153